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Abstract  
The structure of unknown compounds present in herbal products was elucidated using liquid 
chromatography-electrospray ionization-mass spectrometry, direct-infusion electrospray 
ionization-mass spectrometry, and nuclear magnetic resonance. Compounds 1-3 were 
identified as sildenafil analogues, 1 bearing an N-ethylpiperazine moiety instead of an N-
methylpiperazine, and an acetyl group instead of the sulfonyl group, named acetildenafil, 2 
bearing an N-ethylpiperazine moiety instead of an N-methylpiperazine (homosildenafil), and 3 
bearing an N-hydroxylethylpiperazine moiety instead of an N-methylpiperazine, named 
hydroxyhomosildenafil. When analysing products marketed for penile erectile dysfunction or 
marketed as aphrodisiacs, attention should be given to the possible presence of these 
components.  
Introduction  
Sildenafil is the active compound in Viagra®, a prescription medicine for penile erectile 
dysfunction. However, it is also found in aphrodisiacs, mainly advertised as natural products. 
As aphrodisiacs and natural products increase in popularity, especially via the World Wide 
Web, this will be a global problem: consumers are not aware of taking a prescription drug that 
has contraindications. 
Recently, the present authors identified three sildenafil analogues in three different herbal 
products. A completely new analogue 1, named acetildenafil, was identified in product A, oral 
capsules, advertised as 'a firm erection of Mother Nature', based on traditional Chinese 
medicine. Homosildenafil (2) was identified in product B, Chinese oral tablets, labelled as a 
herbal preparation containing Juglans regia (walnut), to be used as an anti-fatigue agent 
according to the package leaflet. However, it was sold as herbal Viagra. Shin et al. (2003) 
published the structure of this analogue using nuclear magnetic resonance (NMR) 
spectroscopy. The compound was discovered in a beverage marketed for erectile 
dysfunction. Hydroxyhomosildenafil (3) was identified in product C, Chinese oral capsules, 
advertised as an herbal alternative for Viagra. 
Based on the structural analogy of these three compounds with sildenafil, similar biological 
activity is to be expected. Pfizer (unpublished data) reported limited pharmacological data for 
hydroxyhomosildenafil, demonstrating biological activity comparable with sildenafil. In Japan, 
one case of liver function impairment was reported that might be due to the use of a product 
containing hydroxyhomosildenafil (Japan, Pharmaceutical and Food Safety Bureau - Health, 
Labor, and Welfare Ministry 2004). Beside this limited information, no data on toxicology and 
efficacy are described in the public (medical) literature for these three analogues. It seems 
there is a tendency towards the development of designer drugs based on sildenafil that might 
present a risk for human health. 
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This paper describes the elucidation of these three compounds using liquid chromatography-
electrospray ionization-mass spectrometry (LC-ESI-MSn), direct-infusion ESI-MSn, and 1H- 
and 13C-NMR. 
Materials and methods  
Samples  
Product A and C were submitted by the Dutch Food and Consumer Product Safety Authority 
for analysis on phosphodiesterase type 5 enzyme (PDE5) inhibitors. Product B was submitted 
by the Dutch Health Care Inspectorate for analysis on sildenafil. 
Materials for LC-ESI-MSn and direct-infusion ESI-MSn  
Sildenafil citrate (pharmaceutical quality) was obtained from Pfizer, Inc. (Groton, USA). 
Tablets of Cialis®, containing 20 mg tadalafil per tablet, were obtained from Eli Lilly 
Nederland B.V. (Houten, The Netherlands). Tablets of Levitra®, containing 20 mg vardenafil 
per tablet, were obtained from Bayer AG (Leverkussen, Germany). Methanol (high-
performance liquid chromatography grade; MeOH) was obtained from Promochem (Wesel, 
Germany). Formic acid (p.A.) was obtained from Merck (Darmstadt, Germany). Ammonium 
hydroxide (NH4OH) was obtained from two suppliers: Merck (32%, extra pure) and Acros 
Organics (Geel, Belgium) (reagent ACS), being of comparable quality. Water was 
demineralized and filtered using a Millipak® 200 0.22-µm filter from Millipore B.V. 
(Amsterdam, The Netherlands). Acidified water was prepared by addition of 2 ml formic acid 
to 1000 ml water and adjusting the pH to 4.0 using NH4OH. 
Materials for NMR  
Solvents and chemicals for NMR analysis - acetone, acetone-d6, acetonitrile (ACN), 
chloroform (CHCl3), deuterated chloroform (CDCl3), deuterium oxide (D2O), dimethylsulfoxide 
(DMSO), MeOH, hydrochloric acid (HCl), C18 material for reversed-phase liquid 
chromatography, sodium hydroxide (NaOH), sodium sulphate (Na2SO4), trimethylsilyl-d4-
propanoic acid, sodium salt (TMSP) - were obtained from commercial sources in the best 
possible quality. 
Materials for (IR)  
Potassium bromide (KBr) powder, spectroscopic grade, used for IR analysis was supplied by 
Anadis Instruments B.V. (Malden, The Netherlands). 
Instrumentation  
Direct-infusion ESI-MSn experiments were carried out using an LCQ Advantage ion-trap mass 
spectrometer equipped with an ESI interface, operated by Xcalibur software version 3.1, from 
Thermo Finnigan B.V. (Breda, The Netherlands). For LC-ESI-MSn experiments, an LC 
system, consisting of a Surveyor autosampler, LC pump and photodiode array (PDA) detector 
(all Thermo Finnigan B.V.), was connected to the mass spectrometer. 
1H-, 13C-, and two-dimensional NMR data were recorded on a JEOL Eclipse 400 
spectrometer. 
IR spectroscopy was performed on a Bruker IFS55 FT-IR spectrometer with a DTGS detector 
and OPUS software version 4.0. 
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Methods  
Preparation of standard and sample solutions  
A standard stock solution was prepared for LC-MSn analysis on sildenafil by dissolving 
sildenafil citrate in MeOH at a concentration of about 450 µg ml-1 equivalent to approximately 
325 µg sildenafil ml-1. The working solution was prepared by diluting the stock solution with 
mobile phase to about 6.5 µg ml-1 sildenafil. Tablets of Cialis® were ground, tablet powder 
was dissolved in MeOH and diluted with mobile phase to about 2 µg ml-1 tadalafil. Similarly, a 
solution of about 2 µg ml-1 vardenafil was prepared from tablets of Levitra®. 
Sample A  
For direct-infusion ESI-MSn, the content of four capsules was homogenized and 
approximately 380 mg were dissolved in 100 ml MeOH by sonification. After filtration over a 
0.45-µm filter, the solution was diluted 1:10 with mobile phase. This solution was also diluted 
1:10 with mobile phase for LC-MSn analysis. For NMR analysis, the compound of interest was 
isolated by dissolving the content of one capsule, approximately 100 mg, in 1 ml DMSO : 
water (20:80 v/v). The product was isolated by reversed-phase liquid chromatography on C18 
material, washing with 10 ml water, followed by 10-ml mixtures of methanol and water with 
increasing amounts of methanol (v/v 10, 40, 60 and 90%). The compound was eluted from 
the column with 10 ml ACN:0.5 M HCl (10:90 v/v). The fractions containing the product were 
pooled and evaporated to dryness under a stream of nitrogen. The residue was dissolved in 2 
ml water, basified using 1 M NaOH solution and extracted with CHCl3. The organic layer was 
washed with water, dried over Na2SO4 and evaporated yielding a white solid. The solid was 
dissolved in CDCl3 for NMR analysis. For IR analysis, the solvent was evaporated and the 
residue prepared as for the KBr tablet. 
Sample B  
For LC-MSn analysis, one tablet was ground and about 50 mg were dissolved in 25 ml MeOH 
by sonification. After filtration over a 0.45-µm filter, the solution was diluted 1:200 with mobile 
phase. For NMR analysis, the compound of interest was isolated by extracting one ground 
tablet three times with 5 ml acetone followed by three times with 5 ml water. The water layer 
was basified using 5 M NaOH solution and extracted three times with 10 ml CHCl3. The 
organic layers were combined, dried with Na2SO4, filtered and evaporated to dryness under a 
stream of nitrogen. The residue was dissolved in approximately 0.8 ml CDCl3. 
Sample C  
For direct-infusion ESI-MSn, the content of three capsules was homogenized and 
approximately 210 mg were dissolved in 50 ml MeOH by sonification. After filtration over a 
0.45-µm filter, the solution was diluted 1:10 with mobile phase. This solution was also diluted 
1:10 with mobile phase for LC-MSn analysis. For qualitative NMR analysis, the compound of 
interest was isolated by extraction of 500 mg sample using acetone and water, and acid/base 
separation as described for sample A. For quantitative NMR analysis, 25 mg were dissolved 
in 0.7 ml D2O containing 0.075% TMSP as internal standard and 0.7 ml acetone-d6. 
LC-ESI-MSn and direct-infusion ESI-MSn  
For chromatographic separation and ultraviolet light detection, the following conditions were 
used: XTerra MS® C18 guard column (20 × 2.1 mm, 3.5 µm) and XTerra MS® C18 analytical 
column (100 × 2.1 mm, 3.5 µm; Waters Chromatography B.V., Etten-Leur, The Netherlands): 
isocratic elution using MeOH : acidified water (50:50 v/v); flow rate at 0.25 ml min-1; column 
temperature of 25°C; injection volume of 20 l; ultraviolet light detection from 200 to 350 nm. 
Mass spectrometry was carried out in positive-ion mode using the ESI interface. Nitrogen was 
used as sheath gas (20 arbitrary units) and as auxiliary gas (10 arbitrary units). Source 
settings used: ion spray voltage 5.0 kV, capillary temperature 300°C, capillary voltage 31 V, 
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tube lens offset 55 V. MS1: mass range m/z = 80-1000. MSn: relevant ions selected and 
fragmented using a collision energy of 40.00 arbitrary units. Instrument conditions were 
checked using sildenafil citrate standard working solution. Samples A and C were analysed 
for PDE5 inhibitors; sample B was analysed for sildenafil only, using a standard analytical 
method (Bakker et al. 2004). 
NMR spectra were recorded using standard single and multipulse sequences for one- and 
two-dimensional NMR spectra. FIDs were zero-filled, apodized using exponential (single 
pulse) or sinebell (multipulse) functions, phase and baseline corrected, and scaled against the 
residual CHCl3 signal at 7.26 (1H) or 77.0 ppm (13C). 
IR measurements were carried out over the spectral range 4000-400 cm-1 with an optical 
resolution of 2 cm-1, and 32 scans were co-added. 
Results and discussion  
Sample A, compound 1  
Based on LC-ESI-MSn, direct-infusion ESI-MSn, 1H- and 13C-NMR, and IR data, the 
compound was identified as a sildenafil analogue bearing an N-ethylpiperazine moiety in 
stead of an N-methylpiperazine, and an acetyl group instead of the sulfonyl group (figure 1). 
   
 
Figure 1.    Structures of sildenafil (1) and analogues homosildenafil (2) and 
hydroxyhomosildenafil (3). Structures: sildenafil (1), (1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-
propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]-sulfonyl]-4-methylpiperazine) R=H; 
2, (1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-
ethoxyphenyl]-sulfonyl]-4-ethylpiperazine) R=CH3; 3, (1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-
propyl-1H-pyrazolo [4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]-sulfonyl]-4-(2-hydroxyethyl)-
piperazine) R=CH2OH; acetildenafil (1), (1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-
pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]-acetyl]-4-ethylpiperazine) R=CH3.  
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Sample A was analysed for PDE5 inhibitors. Although sildenafil, vardenafil and tadalafil are 
absent, an abundant peak at a retention time of 0.8 relative to sildenafil is observed as well in 
the total scan chromatogram of the PDA as in the total ion current (TIC) chromatogram of the 
MS detector. The UV spectrum is very different from sildenafil, vardenafil and tadalafil (table 
1); the most abundant peak in the MS1 spectrum at that retention time is at m/z = 467, 
accompanied with a peak at m/z = 489, indicating the ions [M + H]+ and [M + Na]+ for a 
compound with a molecular mass of 466. Direct-infusion ESI-MS2 showed that the 
fragmentation pattern of m/z 467 is very different from the patterns of [M + H]+ of sildenafil, 
vardenafil or tadalafil (Bakker et al. 2004). The ions m/z = 311 and 313 are observed in the 
mass spectrum of [M + H]+ of both 1 and sildenafil, but the relative intensities are less than 
5% for both ions in 1 compared with 100 respectively 60% in sildenafil (figure 2a, b). 
Table 1.    Retention time (RRT, based on the photo diode array signal) and ultraviolet 
light (UV) maxima of sildenafil, vardenafil, tadalafil and compounds 1-3. 
Compound (product) RRT (min) UVmax (nm) 
Maximum at 292 nm is absent; curving at 246 nm. 
Sildenafil (Viagra®) 1.0 230, 292 
Vardenafil (Levitra®) 1.2 230  
Tadalafil (Cialis®) 1.5 230, 283 
1 Product A 0.8 234, 279 
2 Product B 1.0 230, 292 
3 Product C 1.0 230, 292 
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Figure 2.    MSn spectra of sildenafil standard and of unknown compounds: (a) MS2 spectrum 
of [M + H]+ = 475 of sildenafil, (b) MS2 spectrum of [M + H]+ = 467 of 1 in Product A, (c) MS2 
spectrum of [M + H]+ = 489 of 2 in Product B, (d) MS2 spectrum of [M + H]+ = 505 of 3 in 
Product C, (e) MS3 spectrum of m/z = 475 377 of sildenafil, (f) MS3 spectrum of m/z = 489 
377 of 2 in Product B, (g) MS4 spectrum of m/z = 505 489 377 of 3 in Product C.  
The difference in fragmentation behaviour can be explained by the results from the 1H- and 
13C-NMR data (table 2). The 1H-NMR spectrum (figure 3a) shows an amide proton at 10.8 
ppm, three aromatic protons at 9.14, 8.15 and 7.09 ppm with a coupling pattern characteristic 
for a 1,2,4-substituted aromatic ring. Compared with sildenafil (table 3) (Badwan et al. 2001), 
the proton signals for H15 and H17 are shifted towards lower field consistent with a carbonyl 
group substituting the sulfonyl moiety. The N-methyl, O-ethyl and C-propyl groups give 
signals at the same field as sildenafil. The N-ethyl substituent shows signals at 1.05 and 2.41 
ppm. The C23 methylene group gives a singlet at 3.82 ppm. Broad peaks at 2.54 and 2.68 
could be assigned to the piperazinyl methylene resonances. 
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Table 2.    Nuclear magnetic resonance data of compound 1. 
C# ppm H# ppm Multiplicity 
1 146.8    
4 153.7    
  5 10.8 1H, br, s 
6 147.4    
8 138.5    
9 124.5    
10 38.2 10 4.27 3H, s 
11 27.8 11 2.94 2H, t, J = 7.5 Hz 
12 22.4 12 1.87 2H, m, J = 7.5 Hz 
13 14.1 13 1.08 3H, t, J = 7.4 Hz 
14 129.9    
15 132.3 15 9.14 1H, d, J = 2.2 Hz 
16 120.0    
17 132.5 17 8.15 1H, dd, J = 8.8, 2.4 Hz 
18 112.7 18 7.09 1H, d, J = 9.0 Hz 
19 159.8    
20 65.8 20 4.36 2H, q, J = 7.0 Hz 
21 14.6 21 1.63 3H, t, J = 7.0 Hz 
22 194.9    
31 64.6 23 3.82 2H, s 
24, 28 52.2  2.68 4H, br, m 
25, 27 52.5  2.54 4H, br, m 
29 53.3  2.41 2H, q, J = 7.3 Hz 
30 11.8  1.05 3H, t, J = 7.0 Hz 
 
Table 3.    Nuclear magnetic resonance data of sildenafil citrate (Badwan et al. 2001). 
C# ppm H# ppm Multiplicity 
1 131.55    
4 153.56    
  5 10.83 1H, s 
6 146.83    
8 146.36    
9 128.65    
10 45.57 10 4.15 3H, s 
11 27.64 11 2.85 2H, t 
12 22.15 12 1.78 2H, m 
13 13.95 13 0.90 3H, t 
14 124.39    
15 131.00 15 8.69 1H, d 
16 121.01    
17 138.55 17 7.73 1H, d 
18 112.90 18 7.07 1H, d 
19 159.25    
20 65.97 20 4.29 2H, q 
21 14.43 21 1.56 3H, t 
24, 28 45.80 24, 28 3.03 4H, t 
25, 27 53.91 25, 27 2.43 4H, t 
29 76.69 29 2.24 3H, s 
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Figure 3.    1H-NMR spectra of unknown compounds: (a) 1H-NMR spectrum of 1 in Product A, 
(b) 1H-NMR spectrum of 2 in Product B, (c) 1H-NMR spectrum of 3 in Product C.  
The 13C-NMR spectrum shows all the characteristic resonances for a 1-substituted [3-(6,7-
dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl structure 
element. Compared with sildenafil, the phenyl carbons show minor shifts, which is also 
indicative of a different substituent. The presence of a ketonic C=O is clear from the 
absorption at 194.9 ppm. Quantitative NMR analysis showed that sample A contained 
approximately 15% (w/w) of acetildenafil, which corresponds to 63 mg/capsule. 
The IR spectrum shows peaks at 3315, 1697, 1604, 1494, 1393, 1261 and 1030 cm-1. Bands, 
which could be attributed to a sulphonamide, are absent. 
Sample B, compound 2  
Based on the LC-ESI-MSn and 1H- and 13C-NMR data described below, the unknown 
compound was identified as a sildenafil analogue, in which the N-methylpiperazine moiety is 
substituted by N-ethylpiperazine (figure 1). 
Sample B was analysed for sildenafil. Although a peak is observed showing retention time 
and ultraviolet light spectrum comparable with sildenafil (table 1), the MS1 spectrum does not 
show an ion at m/z = 475 representing [M + H]+ of sildenafil; however, an ion at m/z = 489 is 
present. Although this corresponds to the molecular mass of vardenafil, the active substance 
of Levitra, a relatively new medicine for erectile dysfunction, its retention behaviour on this 
chromatographic system and ultraviolet light spectrum are different (Bakker et al. 2004). 
MS2 spectra of [M + H]+ of sildenafil (m/z = 475) and of the unknown compound (m/z = 489) 
were obtained (figure 2a, c). Both spectra show signals at m/z = 377, 313, 311 and 283. 
According to the fragmentation pathway proposed by Zhong et al. (2002), these ions lack the 
piperazine moiety. As the MS3 spectra of m/z = 377 of both compounds are comparable 
(figure 2e, f), this part of the molecule in both compounds is similar, suggesting that the 
difference of 14 amu (-CH2-) should be in the piperazine moiety. The formation of m/z = 461 
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from 489 suggests the loss of C2H4, indicating the presence of an ethyl group. These findings 
are consistent with the 1H- and 13C-NMR data (figure 3b and table 4). These data are in 
agreement with the data of Shin et al. (2003). 
Table 4.    Nuclear magnetic resonance data of compound 2. 
C# ppm H# ppm Multiplicity 
Atoms in bold show correlation peaks. 
1 146.37    
4 153.56    
  5 10.81 1H, bs 
6 146.86    
8 138.28    
9 124.39    
10 38.12 10 4.26 3H, s 
11 27.65 11 2.92 2H, t, J = 7.5 Hz 
12 22.16 12 1.85 2H, m, J = 7.5 Hz 
13 13.95 13 1.02 3H, t, J = 7.3 Hz 
14 128.57    
15 131.08 15 8.81 1H, d. J = 2.4 Hz 
16 121.02    
17 131.63 17 7.82 1H, dd, J = 8.8, J = 2.5 Hz 
18 112.94 18 7.13 1H, d, J = 8.8 Hz 
19 159.23    
20 65.98 20 4.36 2H, q, J = 7 Hz 
21 14.44 21 1.64 3H, t, J = 7 Hz 
24 46.01 24 3.09 4H, bs 
25 51.71 25 2.53 4H, bs 
29 51.80 29 2.40 1H, q, J = 7.2 Hz 
30 11.85 30 1.02 3H, t, J = 7.3 Hz 
Based on the PDA total scan chromatogram and the assumption that the extinction coefficient 
of sildenafil and homosildenafil are comparable, the amount of homosildenafil in sample B 
was estimated at 142 mg/tablet. 
Sample C, compound 3  
Based on LC-ESI-MSn, direct-infusion ESI-MSn, and 1H- and 13C-NMR data, the compound 
was identified as a sildenafil analogue bearing an N-hydroxylethylpiperazine moiety instead of 
an N-methylpiperazine (figure 1). 
Sample C was analysed for PDE5 inhibitors. An abundant peak is observed with a retention 
time and ultraviolet light spectrum comparable with sildenafil. In de MS1, spectrum peaks are 
present at m/z = 505, 527 and 543, indicating [M + H]+, [M + Na]+ and [M + K]+ for a 
compound with a molecular mass of 504. The MS2 spectrum of [M + H]+ (figure 2d) shows 
peaks at m/z = 487 (loss of H2O), 461 (loss of CH2=CHOH), and 377. M/z = 461 is also 
observed in the MS2 spectrum of m/z = 489 ([M + H]+) of homosildenafil, indicating loss of 
CH2=CH2. M/z = 377 is observed in the MS2 spectra of [M + H]+ of sildenafil and 
homosildenafil, representing the remaining ion after loss of the piperazine moiety. The MS3 
spectrum of m/z = 505 377 from the unknown compound in sample C obtained by direct-
infusion ESI-MS (figure 2g) shows resemblance to the MS3 spectra of m/z = 377 of sildenafil 
and homosildenafil. Based on these results, the structure could be hydroxyhomosildenafil. 
This proposal is supported by the 1H- and 13C-NMR data, which are presented in figure 3(c) 
and table 5. 
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Table 5.    Nuclear magnetic resonance data of compound 3. 
C# ppm H# ppm Multiplicity 
Atoms in bold show correlation peaks. 
1 146.39    
4 153.58    
  5 10.81 1H, bs 
6 146.95    
8 138.33    
9 124.46    
10 38.22 10 4.28 3H, s 
11 27.71 11 2.93 2H, t, J = 7.4 Hz 
12 22.23 12 1.86 2H, h, J = 7 Hz 
13 14.02 13 1.03 3H, t, J = 7.3 Hz 
14 128.82    
15 131.13 15 8.84 1H, d, J = 2.4 Hz 
16 121.12    
17 131.64 17 7.84 1H, dd, J = 8.8, J = 2.4 Hz 
18 113.07 18 7.17 1H, d, J = 8.8 Hz 
19 159.34    
20 66.09 20 4.39 2H, q, J = 7 Hz 
21 14.52 21 1.66 3H, t, J = 7 Hz 
24,28 46.11 24,28 3.1 4H, bs 
25,27 51.93 25,27 2.62 4H, bt, J = 5.4 Hz 
29 58.90 29 2.55 2H, t, J = 5.4 Hz 
30 57.74 30 3.58 2H, t, J = 5.4 Hz 
  OH 2.3 1H, bs 
Quantitative NMR analysis showed that sample C contained approximately 10% (w/w) 
hydroxyhomosildenafil, which corresponds to 45 mg/capsule. 
As three different sildenafil analogues were identified over a short period, it seems there is a 
tendency towards designer drugs for Viagra counterfeits and herbal aphrodisiacs being 
distributed on the market. When analysing these products, attention should be given to the 
possible presence of this type of components. Only screening for the active ingredients of 
prescription drugs such as sildenafil and vardenafil is not sufficient anymore. 
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